5th Nov 2026 12:45
5 November 2026
Surgical Innovations Group plc
(“Surgical Innovations”, “SI” or the "Company")
Director/PDMR Dealings
Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery (“MIS”), was notified yesterday that, on 4 November 2026, David Marsh, Non-Executive Director, sold 5,000,000 ordinary shares of 1p each in Surgical Innovations (“Ordinary Shares”) at a price of 0.325 pence per share.
On the same day, Thalassa Holdings Ltd. purchased 5,000,000 Ordinary Shares of 1p each at a price of 0.325 pence per share. Under MAR, Thalassa Holdings Ltd. is a person closely associated to Duncan Soukup, who is a Non-Executive Director of the Company.
Following this transaction, David Marsh has a beneficial holding in the Company of 26,562,500 Ordinary Shares, representing approximately 2.85% of the issued share capital of the Company. And Thalassa Holdings Ltd. has a beneficial holding in the Company of 219,480,101 Ordinary Shares, representing approximately 23.53% of the issued share capital of the Company.
For further information please contact:
Surgical Innovations Group plc www sigroupplc com
Alex Warnock, CEO Tel: 0113 230 7597
David Anderson, CFO
Singer Capital Markets (Nominated Adviser & Broker) Tel: 020 7496 3000
Alex Bond / Peter Steel / Anastassiya Eley
Walbrook PR (Financial PR & Investor Relations) Tel: 020 7933 8780 or [email protected]
Paul McManus / Alice Woodings Mob: 07980 541 893 / 07407 804 654
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | David Marsh |
2 | Reason for the notification | |
a) | Position/status | Non-Executive Director |
b) | Initial notification/ Amendment | Initial Notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Surgical Innovations Group plc |
b) | LEI | 2138004GHGUH3HUZE156 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 1p GB0004016704 | |||
b) | Nature of the transactions | Sale of Ordinary Shares | |||
c) | Price(s) and volume(s) |
| Price(s) per share | Volume(s) |
|
0.325 pence | 5,000,000 | ||||
| |||||
d) | Aggregated information - Aggregated volume - Price |
5,000,0000.325p
| |||
e) | Date of the transaction | 4 November 2026 | |||
f) | Place of the transaction | Outside of a trading venue | |||
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Thalassa Holdings Ltd |
2 | Reason for the notification | |
a) | Position/status | Person closely associated with Duncan Soukup, Non‑Executive Director |
b) | Initial notification/ Amendment | Initial Notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Surgical Innovations Group plc |
b) | LEI | 2138004GHGUH3HUZE156 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 1p GB0004016704 | |||
b) | Nature of the transactions | Purchase of Ordinary Shares | |||
c) | Price(s) and volume(s) |
| Price(s) per share | Volume(s) |
|
0.325 pence | 5,000,000 | ||||
| |||||
d) | Aggregated information - Aggregated volume - Price |
5,000,0000.325p
| |||
e) | Date of the transaction | 4 November 2026 | |||
f) | Place of the transaction | Outside of a trading venue | |||
About Surgical Innovations Group plc
The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.
Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.
In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.
We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs, the Company’s Resposable portfolio enables healthcare providers to reduce both plastic waste and their CO2 footprint as they strive for net zero.
Further information
Further details of the Group's businesses and products are available on the following websites: www.sigroupplc.com
www.surginno.com www.elementalhealthcare.co.uk
To receive regular updates by email, please contact [email protected]
Related Shares:
Surgical Innovations